Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients
Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients
Portfolio
Kinaset Therapeutics, a biopharmaceutical company developing a next generation anti-inflammatory therapy to treat patients with severe asthma, today announced that the first 24 participants have been dosed in its Phase 1b placebo-controlled study.
This trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of KN-002, a novel and potent inhibitor of all Janus kinase (JAK) isoforms (i.e. JAK1, JAK2, JAK3, TYK2) that is formulated as a dry powder for inhaled delivery to the lung.
Do you want to stay updated about the press releases?